GEN to Present “Drug Discovery Theater” Program at Biotechnica 2010

New Rochelle, NY, October 1, 2010—Genetic Engineering & Biotechnology News (www.genengnews.com) will present two “Drug Discovery Theater” sessions at the upcoming Biotechnica Conference and Trade Show (www.biotechnica.de), which will be held in Hannover, Germany, from October 5-7. The sessions will run from 2 pm until 5:45 pm on Tuesday, October 5, and from 2:45 pm until 5:00 pm Wednesday, October 6, in a presentation theater adjacent to the GEN exhibition booth in Hall 9, Stand 23.

“GEN was honored to have been asked to assemble the panels and speakers for our Drug Discovery Theater program at one of Europe’s most important biotechnology conferences and trade show exhibitions,” said John Sterling, Editor in Chief of GEN. “The scientific drug discovery experts who will speak during our theater program will offer useful and valuable insights on this critical aspect of the drug development process continuum.”

The Drug Discovery Theater program at Biotechnica is as follows:

Tuesday, Oct. 5

2:00 – 2:45 PM

Title: From Academia to Big Pharma - Key Success Factors in the Technology Transfer Process

Panel Chairman: Axel Koch, MBA, Managing Director, ElexoPharm GmbH

Panelists:

Dr. Michael Huhn, European Patent Attorney and Head of the Working Group “Technology Transfer” of the Licensing Executive Society, Germany
Dr. Jörg Knäblein, Head Technology Scouting, Bayer Schering Pharma
Jens Krück, Technology Transfer Manager, Saarland University
Dr. Marion Kronabel, Managing Director, European Association of Pharma Biotechnology (to be confirmed)

2:45 – 3:30 PM

Title: Advances in Molecular Diagnostics and its Impact on the Drug Industry

Stephen Little, Ph.D., Vice President Personalized Healthcare, Qiagen

3:30 – 4:15 PM

Title: Simultaneous Confirmation of Protein Sequence and Quantitation of Post-translational Modifications

Patrick Boyce, Ph.D., Biopharmaceutical Marketing Manager, Europe Waters

4:15 – 5:45 PM

Title:  TGF-ß – An Important Target in Cancer Research

Chairman: Dr. Hubert Heinrichs, Chief Medical Officer, Antisense Pharma

Topic 1:  TGF-ß / TGF-ß2 and its Role in Aggressive Cancer Diseases
Prof. Peter ten Dijke, Professor of Molecular Cell Biology, Leiden University, The Netherlands

Topic 2:   Therapies Targeting TGF-ß - An Overview
Dr. med. Piotr Jachimczak, Member of the American Association for Cancer Research and the European Neuro-Oncology Organization

Topic 3:  Inhibition of TGF-ß2 in High-Grade Glioma Patients - Clinical Results of the International Phase IIb Study (Publ. in press)
Dr. Peter Hau, Attending, Section Leader of the Department NeuroOncology, Associate Professor, University of Regensburg

Wednesday, Oct. 6

2:45 – 3:30 PM

Title: Using IPA to Compare Pathways, Biological Processes Impacted by Celebrex and Vioxx—Case Study in Mechanism of Toxicity Hypothesis Generation

Adam S. Corner, Ph.D., Senior Scientist, Europe, Ingenuity Systems

3:30 – 4:15 PM

Title: Pressure Cycling Technology (PCT): A Novel, Enabling Platform Revolutionizing Biomarker Discovery

Nathan Lawrence, Ph.D.
Vice President of Marketing, Pressure BioSciences

4:15 – 5:00 PM

Title: Bead Based Protein Arrays

Dr. Janet Krege, New Technology Evaluation/R&D

#####

Genetic Engineering & Biotechnology News (www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Translational Medicine.